Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and ...
Actimed will present at several symposia throughout the event, reinforcing its role as a leader in the management and treatment of cancer cachexia and other muscle wasting disorders. These ...
Results from SCOPE to date have enabled Scancell to select Immunobody iSCIB1+, administered needle-free intramuscularly, for further development in patients with selected human leukocyte antigen (HLA) ...
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) Patients ...
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC ...
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
The collaboration pairs Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s deep expertise in immuno-dermatology to identify, validate, and advance ...
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation ...
Gazyva/Gazyvaro is approved for adults with lupus nephritis in the United States and European Union and in over 100 countries for various types of haematological cancers.
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 ...
1. About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保) ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, ...
As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback